Søgning på udtrykket 'hiv' giver 173 resultater
Dokumenter [20]
Sider [7]
Kalender [97]
Nyt fra tidsskrifterne [+20]
Aktuelle smitsomme sygdomme [+20]
Dokumenter [20]
Forfattere: Jan Gerstoft, Nina Weis, Terese L. Katzenstein (Dansk Selskab for Infektionsmedicin), Anders Nyboe Andersen og Jens Fedder (Dansk Fertilitetsselskab).
Version: 3. Endelig guideline: 01.09.2020. Guideline skal revideres senest: 01.09.2023
Arbejdsgruppens medlemmer: Peer Brehm Christensen, Christian Erikstrup, Jan Gerstoft, Terese Katzenstein, Alex Laursen, Suzanne Lunding, Birgitte Mørn og Nina Weis.
Arbejdsgruppen bestod af: Jan Gerstoft, Ann-Brit Eg Hansen, Gitte Kronborg, Jens D. Lundgren, Henrik I. Nielsen, Olav Ditlevsen Larsen, Niels Obel og Alex Laursen
Fællesregional retningslinje for udlevering af forebyggende medicin mod HIV (PrEP), udgivet af Danske Regioner.
medicin i form af f.eks TNF-α hæmmere eller andre immunsupprimerende biologiske lægemidler, hvor der er øget risiko for tuberkulosereaktivering.
Guideline dækker ikke børn, personer med medfødt immundefekt, HIV positive, patienter i dialyse, patienter med dysreguleret diabetes, silicose, erhvervede immundefekter eller patienter i konventionel kortvarig kemoterapi.
Denne guideline omhandler ikke klassisk smitteopsporing blandt tuberkuloseeksponerede eller udredning på mistanke om aktiv tuberkulose.
r (BMSL) til patienter i forhold til risiko for tuberkulose (TB), Humant Papillom Virus (HPV), Hepatitis B og C (HBV og HCV), Varicella Zoster Virus (VZV), Herpes Simplex Virus (HSV), Cytomegalovirus (CMV), Epstein Barr Virus (EBV) og Humant Immundefekt Virus (HIV) og øvrige infektioner.
Vejledningen er udarbejdet af repræsentanter fra Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Reumatologisk Selskab (DRS), Dansk Dermatologisk Selskab (DDS) og Dansk Selskab for Infektionsmedicin (DSI).
Revideret september 2020. Arbejdsgruppen bestod af Suzanne Lunding (formand), Peer Brehm Christensen, Christian Erikstrup, Terese L. Katzenstein, Henrik Krarup, Alex Lund Laursen, Birgitte Mørn og Nina Weis
Udarbejdet af DSI's arbejdsgruppe vedrørende antiretroviral terapi
Arrangeret af Yngre Infektionsmedicinere
Bl.a. om HIV, hepatitis, resistente bakterier og immundefekt
Bl.a. om HIV, hepatitis, influenza og CNS infektioner
Bl.a. om HIV, hepatitis, cystisk fibrose og nye guidelines
Correspondence regarding "Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy"
Bl.a. om sygdom efter udlandsrejse, resistens og kroniske virale infektioner
Henvendelse til Danske regioner
Forfattet af DSI's arbejdsgruppe vedrørende antiviral behandling
Bilag til Retningslinjer for screening og profylakse før behandling med biologiske lægemidler (2023)
Sider [7]
Formål:
At kursisten skal opnå en forståelse af HIV-infektionen herunder viden om dens epidemiologi, patogenese, patofysiologi, diagnose, forebyggelse, behandlingsmuligheder og prognose samt viden om diagnostik og behandlingen af AIDS-definerende sygdomme og de hyppigste sexuelt overførte sygdomme.
Tid og sted:
Hvidovre Hospital. Lokale 10 i undervisningsbygningen.
Delkursusledere:
Ann-Brit Eg Hansen og Ole Kirk.
Program:
Mandag 3. oktober:
10:00-10:15 Velkomst og introduktion (Ann-
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
na Weis, Britta Tarp, Lone Mygind
National Strategi for Hepatitis C (Sundhedsstyrelsen 2023),
Kronisk viral hepatitis:
Nina Weis (tovholder), Peer Brehm Christensen, Alex Lund Laursen
Hepatitis B (2018),
Hepatitis C (2022),
HIV:
Antiretroviral terapi:
Jan Gerstoft (tovholder), Jens Lundgren, Henrik Nielsen, Alex Laursen, Niels Obel, Isik Somuncu, Gitte Kronborg, Ann-Brit Eg Hansen
Antiviral behandling af hiv smittede personer (2024),
Fertilitetsbehandling ved HIV og
terologiske infektioner og kronisk hepatitis:
Dato for næste kursus
2026:
Sted
Odense Universitetshospital
Delkursusledelse
Lone Mygind, Micha Jepsen og Belinda Mössner
Tidligere kurser
4. og 5. december 2023
3. og 4. december 2020
HIV-infektion:
Næste kursus
Efterår 2025 (2 dage):
Sted
Afventer
Delkursusledelse
Ole Schmeltz Søgaard og Lene Ryom Nielsen
Program
Afventer
Tidligere kurser
12. og 13. oktober 2022
7. og 8. oktober 2019
3. og 4. oktober 2016
me og biologisk terrorisme. Specialet er karakteriseret ved et sygdomspanorama hvor sygdommenes prævalens såvel som incidens ændres hurtigt på lokalt og globalt plan. Over de seneste tyve år har specialet udviklet sig til at håndtere behandlingen af HIV og AIDS. I de seneste år er nye alvorlige infektionssygdomme som SARS, fugleinfluenza, West Nile virus, Hanta virus, Nipah virus, og Hendra virus tilkommet. Alvorlige sygdomme som hæmoragisk viral feber forårsaget af Ebola, Lassa, Dengue, Crimean-Co
iklen summerer på en rimelig afbalanceret måde den globale kontrovers, som 2013 var præget af, om hvorvidt ART skal benyttes som forebyggende middel, som led i en individuel-baseret eller en folkesundsbaseret strategi for at reducere smittespredning af HIV. De udfordringer som den vestlige verden, trods udbredt og gratis behandlingstilbud, har med at få styr på smittespredning blandt fx mænd-der-har-sex-med-mænd viser, at det - der intuitivt synes ligefor - ikke nødvendigvis virker når det kommer t
Professor Henrik Nielsen kommenterer: Trods indiskutable fremskridt i den farmakologiske behandling af HIV/AIDS er der fortsat områder med plads til forbedring.
Blandt patienter i kronisk behandling er HAND (HIV-associated neurocognitive disorder) et af disse eksempler. Det har været debatteret om forskelle i antiretrovirale lægemidlers penetrans over blod/hjerne barrieren har betydning for HAND og for AIDS-definerende opportunistisk infektion i hjernen.
Der er ingen tvivl om at koncentr
Professor Jens Lundgren kommenterer: I 2014 var verden optaget af Ebola udbruddet i Vest Afrika – et udbrud der blev erkendt hurtigt (om end den internationale assistance lod vente på sig).
Vedlagte artikel belyser detaljeret hvorledes HIV pandemien startede i 1920’erne og hvor det jo som bekendt tog over 60 år af finde ud at der overhovedet var et problem.
Synes artiklen er godt skrevet og giver et indblik i Afrika for 90 års siden og de ingredienser der skulle til for at ud
Professor Lars Østergaard kommenterer: Jeg vil gerne anbefale vedlagte artikel som julemånedslæsning. Grundene er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den
Professor Jens Lundgren kommenterer: I 2015 nåede WHO sit mål om at få 15 million på behandling. START studiet afklarede også at alle HIV+ personer har gavn af at starte på HIV behandling. Der er fortsat mere end 20 millioner der endnu ikke er startet. Hovedparten bor i ressource svage lande hvor adgang til monitorering af HIV mængden er begrænset og behandlingsskift pga behandlingssvigt er derfor primært drevet af klinik og CD4 tals måling. Omkostning ifm nyttevirkning er central i at forbedre be
dolutegravir, især når det kombineres med TAF fremfor tenofovir DF, forårsager markant vægtøgning. Især hos kvinder med mørk hudfarve. Artiklen gør indtryk af en række grunde:. Da dolutegravir blev markedsført havde det profilen som det eneste HIV præparat uden bivirkninger. Læring: der er ingen medicinske præparater der ikke har nogle bivirkninger, og typen af bivirkninger kan ikke altid forudsiges udfra markedsføringsstudier (fase I-III). Dette faktum er universelt og set for praktisk tage
Professor Jens Lundgren kommenterer: Første lægemiddel mod SARS-CoV-2 udviklet fra ”bunden” – bruger et gammel trick fra HIV medicinen (ritonavir) for at holde plasma koncentrationerne oppe. Læringen er, at det tager tid at lave nye lægemidler helt fra bunden, men det er noget nær en verdensrekord så hurtigt som det skete under pandemien – både hvad angår vacciner (hvor det tog < 1 år fra design ex vivo til markedsføring), men altså ca 2 år for lægemidler som dette.
Professor Lars Østergaard kommenterer: Indimellem kommer der studier, som er så overbevisende, at det sætter en ny behandlingsstandard.
Det kan f.eks. være Lundgrens studie af, hvornår man kan holde op med at give pneumocyste-profylakse til HIV-smittede eller de Gans studiet, der ændrede fik indført dexamethason i retningslinjerne for purulent meningitis.
Her er formentlig et nyt studie, der kommer til at få indflydelse på standardbehandlingen af patienter med svær pneumoni.
Læs en gang - og d
Professor Troels Lillebæk kommenterer: Interessant systematisk review i AIDS om udbytte af screening for tuberkulose infektion (TBI) blandt personer, der lever med HIV (PLHIV) i tuberkulose lav-incidens lande (som Danmark) . Inddraget i alt 51 undersøgelser med 65.930 PLHIV hvoraf 12 % havde en positiv LTBI-test, som var stærkt relateret til oprindelsesland og eksponering for TB ). Forfatterne beretter at 20 TBI-positive personer skulle behandles for at forhindre ét tilfælde af TB, og at antallet, der
Kalender [97]
4. juni 2025, Barcelona, Spanien
4. juni 2025, Barcelona, Spanien
10. november, Glasgow, Skotland
25. september, Stockholm, Sverige
12. september, Hotel Scandic, Østergade 10, 8000 Aarhus C
10. juni, Auditorium 2, Rigshospitalet
27. september 2023, Stockholm, Sverige
24. august 2023, Emil Aarestrup Auditorium, Odense Universitetshospital
23. juli 2023, Brisbane, Australien og virtuelt
7. juni 2023, Rom, Italien
1. juni 2023, Mærsk Tårnet, Panum Instituttet, København
10. maj 2023, Avignon, Frankrig
27. januar 2023, Karen Brahe auditoriet, Odense Adelige Jomfrukloster (og online)
14. december 2022, Statens Institut for Folkesundhed og online
23. oktober 2022, Glasgow, Skotland
20. oktober 2022, Washington DC, USA
12. oktober 2022, Hvidovre Hospital
28. september 2022, Stockholm, Sverige
22. september 2022, Barcelona, Spanien
10. juni 2022, Panum, København
17. maj 2022, Niels K. Jerne auditoriet, Panum Instituttet, København
10. maj 2022, Avignon, Frankrig
6. december 2021, Rigshospitalet
26. november 2021, Panum, København
30. september 2021, Barcelona, Spanien
18. juli 2021, Berlin, Tyskland
28. oktober 2020, Paris, Frankrig
25. oktober 2020, Glasgow, Skotland
28. august 2020, Online og Henrik Dam auditoriet, Maersk Tårnet
10. marts 2020, KolleKolle, Værløse
7. oktober 2019, København
11. september 2019, DGI-byen, København
21. juli 2019, Mexico City, Mexico
22. maj 2019, Rom, Italien
13. maj 2019, København, Odense, Aarhus
6. marts 2019, KolleKolle, Værløse
2. november 2018, Mærsk Tower, København
28. oktober 2018, Glasgow, Skotland
30. maj 2018, Rom, Italien
16. maj 2018, Marseille, Frankrig
4. maj 2018, Hindsgavl, Middelfart
28. februar 2018, Nielsine Nielsen Auditorium, Mærsk Tårnet, København
23. februar 2018, Syddansk Universitet, Odense
1. februar 2018, Nielsine Nielsen auditoriet, Mærsk Tårnet, København
6. oktober 2017, Holst Auditoriet, Mærsk tårnet, København
8. juni 2017, Hvidovre Hospital
4. maj 2017, Odense Universitetshospital
18. april 2017, Auditorium 93, Rigshospitalet
23. oktober 2016, Glasgow, Skotland
3. oktober 2016, Hvidovre Hospital
18. september 2016, Brisbane, Australien
25. maj 2016, Rom, Italien
29. april 2016, Hindsgavl, Middelfart
7. januar 2016, Medicinsk Museion, København
18. december 2015, Emil Aarestrup auditorium, Odense Universitetshospital
24. november 2015, Hvidovre Universitetshospital
8. september 2015, Panum Instituttet, København
18. juni 2015, Rigshospitalet, Teilum B
12. juni 2015, Medicinsk Museion, København
3. juni 2015, Barcelona, Spanien
24. april 2015, Auditorium 93, Rigshospitalet
17. april 2015, Foredragssalen, Statens Serum Institut
19. marts 2015, Auditorium 1, Rigshospitalet
2. november 2014, Glasgow, Skotland
5. oktober 2014, Barcelona, Spanien
5. juli 2014, Sigtuna, Sverige
18. juni 2014, Store Auditorium, Winsløwparken 15, st., 5000 Odense C
22. april 2014, Auditorium 5, Hvidovre Hospital
26. marts 2014, Barcelona, Spanien
20. februar 2014, Rigshospitalet
25. oktober 2013, Hannover auditoriet, Panum Instituttet, København
30. juni 2013, Kuala Lumpur, Malaysia
10. juni 2013, Centre for Medical Parasitology, København
3. maj 2013, Hindsgavl, Fyn
20. marts 2013, Rom, Italien
3. marts 2013, Atlanta, Georgia, USA
14. januar 2013, Auditorium 2, Rigshospitalet
10. november 2012, Auditorium 2, Rigshospitalet
25. oktober 2012, Danmarks Medie- og Journalisthøjskole
23. oktober 2012, Rigshospitalet
2. oktober 2013, San Francisco, USA
27. september 2012, Auditorium 1, Bartholinbygningen, bygning 1241, lokale 135, Aarhus Universitet
29. februar 2012, SSI, København
9. december 2011, Rigshospitalet, københavn
7. november 2011, Auditorium 93, Rigshospitalet
13. maj 2011, Panum instituttet, København
29. april 2011, Auditorium B, Skejby
12. april 2011, Auditorium 100, Campusvej 55, 5230 Odense M, Syddansk Universitet
30. november 2007, Panum Instituttet, København
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
BMC Infectious Diseases
29.10.2024
. Abstract. . Background. Information on the comparison of blood microbiota between human immunodeficiency virus (HIV)-infected and HIV-uninfected patients with suspected sepsis by metagenomic next-generation sequencing (mNGS) is limited. . . . Methods. Retrospectively analysis was conducted in HIV-infected and HIV-uninfected patients with s
BMC Infectious Diseases
29.10.2024
. Abstract. . Background. Anemia is a common complication of HIV infected children and it is enabling HIV disease progression, and decreasing survival. In Ethiopia, there is limited evidence on the prevalence of anemia and its associated factors among HIV infected children particularly in the Awi Zone. Therefore, this study aimed to assess the magnitude and associated factors of anemia among HIV infected children on ART aged
BMC Infectious Diseases
29.10.2024
. Abstract. . Background. Older people with HIV (PWH) are at risk of polypharmacy (taking multiple medications). Most medications may be necessary and indicated to manage HIV (e.g., antiretroviral therapy [ART]) and HIV-associated comorbidities. However, some are potentially inappropriate medications (PIMs), defined as causing greater harm than benefit, which leads to medication overload. The objective of this study was to c
AIDS
29.10.2024
Objectives: . Worldwide, adult men experience an excess burden of tuberculosis (TB) disease compared to women, but few studies have examined sex differences in TB among people with HIV. In this study, we aimed to investigate sex differences in TB infection and disease among people with HIV in Rio de Janeiro, Brazil. Design: . Analysis of data from a randomized controlled trial and retrospective cohort study. Methods: . We analyzed data from two studies conducted between 2005 and 2017. The THRio Study (20
AIDS
29.10.2024
Objective: . We aimed to synthesize clinical and economic outcomes of rapid start versus non-rapid antiretroviral therapy (ART) in people with HIV (PWH) in real-world settings. Methods: . A search was conducted in PubMed, Embase, Web of Science, and ProQuest from January 2017 to January 2023, supplementing a previous search by Ford et.al, 2018. Observational studies investigating clinical or economic outcomes of rapid start ART versus non-rapid ART in PWH were included. Clinical outcomes were mortality, l
AIDS
29.10.2024
Background: . Frailty occurs at higher rates and younger ages among people with HIV (PWH) compared to the general population and is often attributed to chronic inflammation and subsequent immune exhaustion. We assessed how inflammatory biomarkers are associated with frailty among PWH. Methods: . The Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort is comprised of adult PWH in care at 10 sites, and harmonizes demographic, clinical, and patient-reported outcomes (PRO) data. A
AIDS
29.10.2024
Objective: . The study aimed to assess the impact of smoking exposure on major clinical events (MCE) in a real-life setting of people living with HIV (PWH). Design: . Observational longitudinal multicentre cohort study from Italy. Methods: . Consecutive 983 PWH were enrolled in “STOP Smoking in HIV people” (STOPSHIV) projects and followed from July 2014 until September 2023. The observed MCE defined as cardiovascular (CV) events, neoplastic diseases or death for any reason was assessed according smok
Clinical Infectious Diseases
29.10.2024
Abstract . Introduction . The equity-focused ILANA study evaluated feasibility, acceptability, appropriateness of delivering on-label two-monthly cabotegravir and rilpivirine (CAB+RPV) injections for HIV-1 therapy in clinics and community settings.Methods . The study, which mandated inclusive recruitment, was conducted May-December 2022 at six UK sites. Injections were delivered in clinic (months 1-6), and in clinic or community setting according to patient choice (months 6-12). Surveys were completed at ba
Journal of Acquired Immune Deficiency Syndromes
27.10.2024
Background: . Discussion of HIV and other sexually transmitted infections (STIs) among sex partners facilitates risk reduction. We evaluated HIV/STI-related communications, including broad assessment of any self-reported discussion of the topic and specific discussion of each partners’ HIV status, among a historically marginalized and presently criminalized community of sexual and gender minorities (SGM) in Nigeria. Methods: . From 2013-2018, we enrolled SGM aged 18+ in Lagos or 16+ in Abuja who reporte
Journal of Acquired Immune Deficiency Syndromes
27.10.2024
Background: . Little is known about the effect of HCV treatment on sexual risk behaviour among men who have sex with men (MSM) with HIV by treatment type (IFN-based vs DAA-based). Setting: . MSM with HIV and recently acquired HCV infection enrolled in the observational MOSAIC cohort. Methods: . Using data from 2009-2018, we evaluated risk behaviour through a validated HCV risk score (where ≥2 indicated high risk) and its individual risk behaviours. Levels of risk behaviour before, during and after trea
Journal of Acquired Immune Deficiency Syndromes
27.10.2024
Background: . Screening for depression remains a priority for people living with HIV (PLWH) accessing care. The nine-item Patient Health Questionnaire (PHQ-9) is a widely used depression screening tool, but has limited accuracy when applied across various cultural contexts. We aimed to evaluate the performance of alternative PHQ-9 scoring algorithms in sub-Saharan African PLWH. Setting: . five HIV programs in Cameroon, Côte d’Ivoire, Kenya, Senegal and the Republic of Congo. Methods: . Adult PLWH were
BMJ Open
27.10.2024
. Objectives. The objective of this study is to examine the zonal-wide load undetectable state and predictors among children and adolescents living with HIV at South Gondar health institutions, 2023. . Design. A retrospective cohort study. . Setting. South Gondar Health Institutions, Northwest, Ethiopia. . Participants. We recruited 430 children and adolescents living with HIV who had a follow-up at the antiretroviral therapy (ART) clinic at health institutions from 1 June 2016 to 30 April 2023. . Outco
BMC Infectious Diseases
27.10.2024
. Abstract. . Background. Anemia is a common complication of HIV infected children and it is enabling HIV disease progression, and decreasing survival. In Ethiopia, there is limited evidence on the prevalence of anemia and its associated factors among HIV infected children particularly in the Awi Zone. Therefore, this study aimed to assess the magnitude and associated factors of anemia among HIV infected children on ART aged
BMC Infectious Diseases
27.10.2024
. Abstract. . Background. Anemia is a common complication of HIV infected children and it is enabling HIV disease progression, and decreasing survival. In Ethiopia, there is limited evidence on the prevalence of anemia and its associated factors among HIV infected children particularly in the Awi Zone. Therefore, this study aimed to assess the magnitude and associated factors of anemia among HIV infected children on ART aged
BMC Infectious Diseases
27.10.2024
. Abstract. . Background. Older people with HIV (PWH) are at risk of polypharmacy (taking multiple medications). Most medications may be necessary and indicated to manage HIV (e.g., antiretroviral therapy [ART]) and HIV-associated comorbidities. However, some are potentially inappropriate medications (PIMs), defined as causing greater harm than benefit, which leads to medication overload. The objective of this study was to c
BMC Infectious Diseases
27.10.2024
. Abstract. . Background. Older people with HIV (PWH) are at risk of polypharmacy (taking multiple medications). Most medications may be necessary and indicated to manage HIV (e.g., antiretroviral therapy [ART]) and HIV-associated comorbidities. However, some are potentially inappropriate medications (PIMs), defined as causing greater harm than benefit, which leads to medication overload. The objective of this study was to c
BMC Infectious Diseases
26.10.2024
. Abstract. . Background. Sierra Leone faces a significant challenge in addressing HIV/AIDS, particularly among adolescent girls and young women. This age group is considered highly vulnerable due to biological factors and social inequalities. Understanding the prevalence of HIV testing in this demographic is crucial for designing effective prevention and treatment strategies. This study investigated the spatial distribution
PLoS One Infectious Diseases
26.10.2024
e de Wit, Hansjakob Furrer, Lukas Fenner, The Opportunistic Infections Project Working Group of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord . Introduction HIV replication leads to a change in lymphocyte phenotypes that impairs immune protection against opportunistic infections. We examined current HIV replication as an independent risk factor for tuberculosis (TB). Methods We included people living with HIV from 25 European cohorts 1983–2015. Individuals
PLoS One Infectious Diseases
26.10.2024
by Robert A. Domaoal, Jeni Vuong, Amy Zheng, Mervi Detorio, Bharat S. Parekh, Ernest L. Yufenyuy . Background We developed the HIV Triplex multiplex bead assay to identify and serotype HIV infection with high sensitivity and specificity; and distinguish recent from long-term HIV-1 infections. It can facilitate accurate incidence estimation, while reducing the number of tests and blood collected, which is highly desirable for use in future studies and surveys. Using previously collected, treatment-naive lon
PLoS One Infectious Diseases
25.10.2024
old Junior Sadio, Harold Régis Kouanfack, Rodion Yao Konu, Fifonsi Adjidossi Gbeasor-Komlanvi, Gagnon Kwami Azialey, Herbert Kokou Gounon, Martin Kouame Tchankoni, Amivi Phyllis Amenyah-Ehlan, Anoumou Claver Dagnra, Didier Koumavi Ekouevi . Introduction HIV self-testing is a complementary screening strategy that could facilitate access to HIV care services for street adolescents. The objectives of this study were to assess the acceptability and feasibility of HIV self-testing and their associated factors,
Aktuelle smitsomme sygdomme [+20]
Der er mere end 20 resultater, måske du vil se
flere resultater her?
Eurosurveillance latest updates
18.10.2024
. Background. Sweden reached the UNAIDS 90–90–90 target in 2015. It is important to reassess the HIV epidemiological situation due to ever-changing migration patterns, the roll-out of PrEP and the impact of the COVID-19 pandemic. . . Aim. We aimed to assess the progress towards the UNAIDS 95–95–95 targets in Sweden by estimating the proportion of undiagnosed people with HIV (PWHIV) and HIV incidence trends. . . Methods. We used routine laboratory data to inform a biomarker model of time since
Medscape Infectious Diseases
4.10.2024
Gilead Sciences said on Wednesday it has granted royalty-free licenses to six generic drug manufacturers to make and sell cheaper copycat versions of its HIV prevention. . Reuters Health Information
Eurosurveillance latest updates
20.09.2024
. Background. In the Netherlands, HIV pre-exposure prophylaxis (PrEP) has been available since 2019. However, the extent of PrEP use prior to HIV diagnosis and development of PrEP-resistance-associated mutations (RAMs) is not known. . . Aim. We assessed prior PrEP use and potential transmission of PrEP RAMs among men who have sex with men (MSM) and transgender persons (TGP) with a new HIV diagnosis in the Netherlands. . . Methods. Data on prior PrEP use between 1 January 2018 and 31 December 2022 were
Morbidity and Mortality Weekly Report (MMWR)
13.09.2024
This report found that as of 2022, none of the 2025 U.S. National HIV/AIDS Strategy goals for improving quality of life among people with diagnosed HIV were met.
Medscape Infectious Diseases
29.07.2024
The newest stem cell recipient to test negative for HIV after cancer treatment had a donor with a single — rather than double — gene mutation that is opening the donor pool in renewed cure efforts. . Medscape Medical News
Eurosurveillance latest updates
20.07.2024
. Background. Recent migration trends have shown a notable entry of Latin American asylum seekers to Madrid, Spain. . . Aim. To characterise the profile of asylum-seeking Latin American migrants who are living with HIV in Spain and to outline the barriers they face in accessing HIV treatment. . . Methods. A prospective cohort study was conducted between 2022 and 2023 with a 6-month follow-up period. Latin American asylum seekers living with HIV were recruited mainly from non-governmental organisations
Medscape Infectious Diseases
5.07.2024
Patients at a high risk for HIV infection who received preexposure prophylactic injections with lenacapavir had 100% efficacy in a phase 3 clinical trial. . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
21.06.2024
This report describes a CDC-funded program that delivered approximately 440,000 HIV self-tests to U.S. residents.
Medscape Infectious Diseases
21.05.2024
Parents with HIV who are not on anti-retroviral therapy or who do not have adequate viral suppression should be advised against breastfeeding, the group said. . MDedge News
Medscape Infectious Diseases
3.05.2024
The cosmetic procedures took place at a spa performing microneedling facials using unsterile injection practices. . Medscape Medical News
Medscape Infectious Diseases
26.04.2024
A large study reveals an increased risk for adverse cardiovascular events but not for liver disease progression in adults with MASLD disease and HIV infection. . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
26.04.2024
This report describes an investigation of multiple HIV infections among people who received microneedling facials.
Eurosurveillance latest updates
15.03.2024
. Background. Some migrant men who have sex with men (MSM) acquire HIV in France. . . Aims. We investigated, in migrant MSM receiving HIV care in France, the (i) rate of post-migration-HIV acquisition in France, (ii) delay between arrival and HIV acquisition and (iii) factors affecting HIV acquisition within 1 year after migration. . . Methods. This cross-sectional study focused on ≥ 18-year-old MSM born outside France, receiving HIV care in the Paris region. Information on migration history,
Medscape Infectious Diseases
11.03.2024
Semaglutide improved MASLD in this population, and weight loss associated with its use resulted in no significant changes in physical function, according to two presentations at CROI. . Medscape Medical News
Medscape Infectious Diseases
8.03.2024
A nurse-led multicomponent strategy significantly reduced systolic blood pressure and non-HDL cholesterol in HIV patients and should be included in HIV primary care programs. . Medscape Medical News
Medscape Infectious Diseases
6.03.2024
The World Health Organization (WHO) said on Tuesday resistance to GSK's HIV drug dolutegravir has exceeded levels observed during its trials, citing observational and survey. . Reuters Health Information
Medscape Infectious Diseases
5.03.2024
The last attempt in a generation of HIV vaccine development ended in disappointment, but investigators are starting over because they believe the human body can make antibodies for HIV. . Medscape Medical News
Medscape Infectious Diseases
5.03.2024
President Joe Biden's administration on Monday urged a U.S. appeals court to preserve a federal mandate that requires health insurers to cover preventive care services. . Reuters Health Information
Medscape Infectious Diseases
28.02.2024
British drugmaker GSK said on Wednesday its long-acting injectable HIV therapy showed promise in keeping the viral load suppressed compared to daily oral treatment,. . Reuters Health Information
Medscape Infectious Diseases
26.02.2024
The smallpox vaccine effectively induces immunity against mpox virus infection in patients with HIV, although patients with low lymphocyte counts require booster doses. . Medscape Medical News